The pathogenesis of Thyroid Eye Disease (TED) has been suggested as due to signal enhancement in orbital fibroblasts as a result of autoantibody-induced, synergistic, interaction between the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). This interaction has been explained by a "receptor cross talk", mediated via β-arrestin binding. Here, we have examined if this interaction can be mediated via direct receptor contact using modeling and experimental approaches. First, we docked a model of the leucine rich domain (LRD) of the TSHR ectodomain (ECD) to an available cryo-EM based structure of the active-state IGF-1R dimer and demonstrated the stability of the complex using molecular dynamics (MD) simulations. We then extended the complex with the full-length TSHR and the transmembrane helices of the IGF1R and a 3000 ns simulation also showed stability of this complex. We then performed co-immunoprecipitation studies with anti-TSHR and anti-IGF-1R antibodies using cells expressing the IGF-1R and the full-length TSHR and also cells that expressed the IGF-1R and only the TSHR-ECD and, therefore, unable to bind β-arrestin. These studies showed a 360 kD complex protein in the immunoprecipitation which was present in both the full-length TSHR and the TSHR-ECD-only expressing cells evidencing a direct interaction of receptors via their ectodomains in the absence of arrestin. Co-localized staining of TSHR and IGF1R in the TSHR-ECD cells further supported this direct interaction. These data showed that the TSHR and IGF-1R can interact directly and in the absence of β-arrestin binding. Understanding these interactions is important in the pathogenesis of TED and its therapeutic intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/endocr/bqaf009 | DOI Listing |
Endocrinology
January 2025
Thyroid Research Unit, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
The pathogenesis of Thyroid Eye Disease (TED) has been suggested as due to signal enhancement in orbital fibroblasts as a result of autoantibody-induced, synergistic, interaction between the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). This interaction has been explained by a "receptor cross talk", mediated via β-arrestin binding. Here, we have examined if this interaction can be mediated via direct receptor contact using modeling and experimental approaches.
View Article and Find Full Text PDFEndocrinology
August 2024
Thyroid Research Unit, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 10019, New York, USA.
The TSH receptor (TSHR) and its many forms are the primary antigens of Graves' disease as evidenced by the presence of TSHR antibodies of differing biological activity. The TSH holoreceptor undergoes complex posttranslational changes including cleavage of its ectodomain and oligomer formation. We have previously shown that the TSHR exists in both monomeric and dimeric structures in the thyroid cell membrane and have demonstrated, by modeling, that the transmembrane domains (TMD) can form stable dimeric structures.
View Article and Find Full Text PDFMol Pharm
August 2024
Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
Thyroid cancer is the most common endocrine cancer, with differentiated thyroid cancers (DTCs) accounting for 95% of diagnoses. While most DTC patients are diagnosed and treated with radioiodine (RAI), up to 20% of DTC patients become RAI refractory (RAI-R). RAI-R patients have significantly reduced survival rates compared to patients who remain RAI-avid.
View Article and Find Full Text PDFJ Mol Graph Model
June 2024
Thyroid Research Unit, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; James J. Peters VA Medical Center, New York, NY, USA.
The receptor for thyroid stimulating hormone (TSHR), a GPCR, is the primary antigen in autoimmune hyperthyroidism (Graves' disease) caused by stimulating TSHR antibodies. While we have previously published a full length model of the TSHR, including its leucine rich domain (LRD), linker region (LR) and transmembrane domain (TMD), to date, only a partial LRD (aa 21-261) stabilized with TSHR autoantibodies has been crystallized. Recently, however, cryo-EM structures of the full-length TSHR have been published but they include only an incomplete LR.
View Article and Find Full Text PDFEndocrinology
September 2023
Thyroid Research Unit, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
The thyroid-stimulating hormone receptor (TSHR) transmembrane domain (TMD) is found in the plasma membrane and consists of lipids and water molecules. To understand the role of TSHR-associated water molecules, we used molecular dynamic simulations of the TMD and identified a network of putative receptor-associated transmembrane water channels. This result was confirmed with extended simulations of the full-length TSHR with and without TSH ligand binding.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!